Speakers

Aaron Hambrick

Aaron Hambrick

Associate Scientific Director, Medical Payer Strategy - Psychiatry

Abbvie

Adam Phipps

Associate Vice President, Government Payer Strategy, Alzheimer's (US)

Eli Lilly

Ali Benakila

Ali Benakila

Global Pharma Dx Strategy Leader

Roche

Andreas Jeromin, Stealth Mode - Market Access for CNS Therapeutics

Andreas Jeromin

Chief Scientific Officer

New Diagnostic Company emerging from Stealth Mode

Brenda Hendron, LabCorp - Market Access for CNS Therapeutics

Brenda Hendron

VP, Market Access

LabCorp

Camilla Gomiero

Camilla Gomiero

VP, Business Development and Commercial Strategy

Engrail Therapeutics

Chuck Collins, The HSS Group - Market Access for CNS Therapeutics

Charles Collins

President

The HSS Group

Damon Harrell

Damon Harrell

Vice President & General Manager, Psychiatry Franchise

Formerly Alkermes

Elicia DeParolesa CVS Health - Market Access for CNS Therapeutics

Dr. Elicia DeParolesa, PharmD

Sr. Manager: Clinical Product Design, Strategy and Innovation

CVS Health

Ginger Johnson, Lumanity - Market Access for CNS Therapeutics

Ginger Johnson

Senior Vice President, Strategy Consulting

Lumanity

Glenn Harris

Glenn Harris

Director of Business Development, Research Partnerships & the Drug Discovery Lead

Rainwater Charitable Foundation

Julio Rojas

Associate Professor of Neurology

UCSF

Kevin Lanzo, Pharmaka Clinical Consultant - Market Access for CNS Therapeutics

Kevin Lanzo

President; Principal Consultant

Pharmaka Clinical Consulting

Kristophe Diaz

Kristophe Diaz

Executive Director & Chief Science Officer

Cure PSP

Shaheen Lakhan

Chief Medical & Scientific Officer

Click Therapeutics

Shawn Carlson, Roche - Market Access for CNS Therapeutics

Shawn Carlson

VP Head of US Market Access

Roche

Steve Beller, Neurolief - Market Access for CNS Therapeutics

Steve Beller

Chief Commercial Officer

Neurolief

VIEW PROGRAM
REGISTER
PARTNER